During the past decade, Mercy Health Partners conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Mercy Health Partners" are "Ovarian Neoplasms" (2 trials). Many other conditions were trialed in "Mercy Health Partners" in a lesser frequency.

Most popular intervention types in "Mercy Health Partners" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Doxorubicin HCl Liposome Injection" (1 trials), "TLK286 HCl for injection" (1 trials), "TLK286 in Combination with Carboplatin" (1 trials), "doxorubicin HCl liposome injection" (1 trials) and "topotecan hydrochloride for injection" (1 trials). Other intervention names were less common.

The vast majority of trials in "Mercy Health Partners" are 2 trials for "Female" genders.

Currently, there are NaN active trials in "Mercy Health Partners". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Mercy Health Partners, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Mercy Health Partners, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".